A review of antibiotic therapy for pelvic inflammatory disease
Rui Duarte1, Daniele Fuhrich2, Jonathan D C Ross3
1University of Birmingham, Birmingham, UK.
Insights
This review examines antibiotic treatments for pelvic inflammatory disease (PID) recommended by IUSTI and CDC. Evidence supports these therapies, though cure rates vary due to differing trial criteria, with few adverse events reported.
Area of Science:
- Gynecology
- Infectious Diseases
- Pharmacology
Background:
- Pelvic inflammatory disease (PID) is a common gynecological condition with serious long-term consequences like infertility and ectopic pregnancy.
- Current management guidelines for PID are provided by the International Union against Sexually Transmitted Infections (IUSTI) and the US Centers for Disease Control and Prevention (CDC).
Purpose of the Study:
- To review and summarize the evidence supporting antibiotic regimens recommended by IUSTI and CDC for treating PID.
- To identify key differences in treatment recommendations between IUSTI and CDC guidelines, particularly regarding inpatient and outpatient antibiotic options.
Main Methods:
- Systematic review of existing clinical trials and evidence evaluating antibiotic therapies for PID.
- Comparative analysis of IUSTI and CDC treatment guidelines for PID management.
Main Results:
- Evidence supports the efficacy of recommended antibiotic regimens for PID, with generally high cure rates observed across studies.
- Variations in reported cure rates may be attributed to differences in diagnostic criteria and patient evaluation methods used in clinical trials.
- Adverse events necessitating treatment discontinuation are infrequent, indicating a favorable safety profile for recommended therapies.
Conclusions:
- The antibiotic therapies recommended by IUSTI and CDC for PID are supported by available evidence.
- Further research with longer follow-up periods is needed to fully assess the long-term sequelae and outcomes associated with PID treatment.
Abstract:
Pelvic inflammatory disease (PID) is a gynaecological inflammatory disorder with a high incidence that can lead to sequelae such as infertility, ectopic pregnancy and chronic pelvic pain. The International Union against Sexually Transmitted Infections (IUSTI) and the US Centers for Disease Control and Prevention (CDC) have issued treatment recommendations for the management of PID. The purpose of this review is to summarise the available evidence for the use of IUSTI- and CDC-recommended antibiotic therapies for PID. The main differences between recommendations concern alternative regimens for inpatient treatment and the use of oral moxifloxacin as an alternative outpatient regimen in the IUSTI guidelines. There is evidence supporting the use of the recommended antibiotic regimens, although with some variation in reported cure rates. This variation can be explained, in part, by the different diagnostic and evaluation criteria used in different trials. Adverse events that require discontinuation of antibiotic therapy are rarely observed. The main limitation of the current available evidence is the short-term follow-up, which does not allow full evaluation of the risks of long-term sequelae.
More Related Videos
Related Concept Videos
01:30Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:17Urinary Tract Infection IV: Nursing Management
01:21Intrauterine Drug Delivery Systems
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy